IN2014MN01594A - - Google Patents

Info

Publication number
IN2014MN01594A
IN2014MN01594A IN1594MUN2014A IN2014MN01594A IN 2014MN01594 A IN2014MN01594 A IN 2014MN01594A IN 1594MUN2014 A IN1594MUN2014 A IN 1594MUN2014A IN 2014MN01594 A IN2014MN01594 A IN 2014MN01594A
Authority
IN
India
Prior art keywords
agent
strain
mtb
allergic
asthma
Prior art date
Application number
Inventor
Iglesias Pere Joan Cardona
Riera Isabel Amat
Moreno Blanca Reyes
Fabregat Maria Mercè Amat
Original Assignee
Archivel Farma Sl
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Archivel Farma Sl filed Critical Archivel Farma Sl
Publication of IN2014MN01594A publication Critical patent/IN2014MN01594A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/001—Preparations to induce tolerance to non-self, e.g. prior to transplantation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A61P31/06—Antibacterial agents for tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/577—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 tolerising response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Transplantation (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention relates to an agent for the treatment or prevention of an allergic condition such as asthma in a mammal. The agent comprises fragments of a complex (MTB C) strain. These particular fragments may be from a virulent MTB C strain and/or in the form of a liposome composition. The agent may include further components such as a liposome forming agent and/or particular proteins from the MTB C strain. A particular allergic response that may be treated by the agent of the invention is allergic asthma. A pharmaceutical composition comprising the agent is also provided. Administration of the agent described herein significantly attenuates airway hyperresponsiveness eosinophilia and lymphocytosis in the airways of sensitized animals. The effectiveness of the agent exceeds on all the evaluated parameters the commercial vaccine BCG Danish 1331 Strain.
IN1594MUN2014 2012-01-12 2012-01-12 IN2014MN01594A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2012/000353 WO2013104943A1 (en) 2012-01-12 2012-01-12 Mtb-c vaccine against asthma

Publications (1)

Publication Number Publication Date
IN2014MN01594A true IN2014MN01594A (en) 2015-05-08

Family

ID=45852617

Family Applications (1)

Application Number Title Priority Date Filing Date
IN1594MUN2014 IN2014MN01594A (en) 2012-01-12 2012-01-12

Country Status (15)

Country Link
US (1) US9682042B2 (en)
EP (1) EP2802345B1 (en)
CN (1) CN104411326B (en)
AU (1) AU2012365465B2 (en)
BR (1) BR112014017217B1 (en)
CA (1) CA2861074C (en)
DK (1) DK2802345T3 (en)
ES (1) ES2670493T3 (en)
IN (1) IN2014MN01594A (en)
NO (1) NO2802345T3 (en)
PL (1) PL2802345T3 (en)
PT (1) PT2802345T (en)
RU (1) RU2602771C2 (en)
WO (1) WO2013104943A1 (en)
ZA (1) ZA201405107B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN103720657B (en) * 2013-11-19 2017-01-04 广东丸美生物技术股份有限公司 The preparation method of a kind of deformable liposome, and the transmutability liposome of preparation
RU2652752C1 (en) * 2017-06-15 2018-04-28 Федеральное государственное бюджетное научное учреждение "Научно-исследовательский институт фундаментальной и клинической иммунологии" Method of treatment of bronchial asthma
EP3797791A1 (en) * 2019-09-26 2021-03-31 Universidad De Zaragoza Therapeutic efficacy by pulmonary delivery of live attenuated mycobacteria

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ZA961412B (en) 1995-02-22 1996-08-26 Adcock Ingram Ltd A method for the isolation and purification of lipid cell-wall components
GB9813100D0 (en) 1998-06-18 1998-08-19 Secr Defence Method of forming liposomes
US20030022854A1 (en) 1998-06-25 2003-01-30 Dow Steven W. Vaccines using nucleic acid-lipid complexes
BR0103887C1 (en) 2001-07-17 2005-11-08 Univ Minas Gerais Immunogenic compositions containing biodegradable microspheres encapsulating antigens, gene vectors and adjuvants
ES2231037B1 (en) 2003-10-31 2005-12-16 Archivel Technologies, Sl USEFUL IMMUNOTHERAPIC AGENT FOR THE COMBINED TREATMENT OF TUBERCULOSIS IN ASSOCIATION WITH OTHER PHARMACOS.
EP1761662A4 (en) 2004-07-01 2010-02-03 Univ California HIGH FLOW PROTEOMICS
EP2426141B1 (en) 2005-04-29 2014-10-01 GlaxoSmithKline Biologicals S.A. Method for preventing or treating M tuberculosis infection
US20070059318A1 (en) 2005-08-15 2007-03-15 Balu-Iyer Sathy V Lipid nano particulates containing antigens as cancer vaccines
WO2008051245A2 (en) 2005-12-02 2008-05-02 Novartis Ag Nanoparticles for use in immunogenic compositions
TW200806317A (en) 2006-03-20 2008-02-01 Wyeth Corp Methods for reducing protein aggregation
CA2649528A1 (en) * 2006-04-20 2007-11-01 Tokai University Educational System Therapeutic agent for allergy containing liposome having oligosaccharide on its surface
JP5917789B2 (en) 2006-10-10 2016-05-18 ジャイナ ファーマシューティカルズ，インコーポレーテッド Aqueous system, composition, method and use thereof for the manufacture of lipid-based pharmaceutical compounds
ES2307402B1 (en) 2006-10-30 2009-09-30 Archivel Farma, S.L. PROFILACTIC VACCINE AGAINST TUBERCULOSIS.
CN101969976A (en) 2008-01-11 2011-02-09 美国政府健康与人类服务部秘书处 Peptide Vaccines and Vaccination Strategies Against Mycobacteria
ES2335177B1 (en) * 2008-09-19 2011-02-28 Archivel Farma, S.L. PROPER IMMUNOTHERAPEUTIC AGENT FOR THE PRIMARY PROFILAXIS OF TUBERCULOSIS.
ES2714383T3 (en) 2009-04-24 2019-05-28 Statens Seruminstitut TB vaccine against tuberculosis to prevent reactivation
PL2651436T3 (en) 2010-12-14 2016-10-31 Mycobacterium antigenic composition

Also Published As

Publication number Publication date
EP2802345B1 (en) 2018-03-07
US9682042B2 (en) 2017-06-20
RU2602771C2 (en) 2016-11-20
BR112014017217A2 (en) 2017-06-13
AU2012365465B2 (en) 2017-05-18
WO2013104943A1 (en) 2013-07-18
CA2861074C (en) 2018-11-06
ES2670493T3 (en) 2018-05-30
PL2802345T3 (en) 2018-08-31
BR112014017217A8 (en) 2017-07-04
BR112014017217B1 (en) 2023-01-17
RU2014133042A (en) 2016-02-27
EP2802345A1 (en) 2014-11-19
NO2802345T3 (en) 2018-08-04
AU2012365465A1 (en) 2014-08-21
PT2802345T (en) 2018-04-24
CN104411326B (en) 2018-02-02
ZA201405107B (en) 2020-11-25
DK2802345T3 (en) 2018-04-30
CA2861074A1 (en) 2013-07-18
US20150132364A1 (en) 2015-05-14
CN104411326A (en) 2015-03-11

Similar Documents

Publication Publication Date Title
EA201690541A1 (en) DRY POWDER PREPARATION CONTAINING PHOSPHODESTERASE INHIBITOR
WO2014045254A3 (en) Human betacoronavirus lineage c and identification of n-terminal dipeptidyl peptidase as its virus receptor
EA201390559A1 (en) SUPPRESSION OF IMMUNE RESPONSE BY THE TYPE OF HYPERSENSITIVITY BY NON-DOMINAL ANTIGEN, RECEIVED FROM THE MATERIAL OF SOURCE ALLERGENS
HK1212249A1 (en) Bioconjugates comprising modified antigens and uses thereof
IN2015DN00376A (en)
MX2022004103A (en) An inhalable rapamycin formulation for treating age-related conditions.
WO2014127917A8 (en) Combination of vaccination and inhibition of the pd-1 pathway
IN2015KN00414A (en)
HK1218837A1 (en) Compositions and methods
EA201291306A1 (en) COMPOSITION OF DRY POWDER CONTAINING ANTIMUSCARINE MEANS
MX2016010373A (en) Rapamycin for the treatment of lymphangioleiomyomatosis.
WO2013098655A3 (en) Vaccines directed against human enteroviruses
MX381173B (en) RAPAMYCIN FOR THE TREATMENT OF LYMPHANGIOLEIOMYOMATOSIS.
WO2013059559A3 (en) Compounds and methods for enhancing innate immune responses
MX2016009306A (en) Epicutaneous immunorebalancing.
WO2014016548A3 (en) Pharmaceutical composition comprising olodaterol and one or more further active pharmaceutical ingredient
MX364800B (en) Improved long-acting tilmicosin and use thereof in the treatment of bovine respiratory disease complex (brdc) and in the dry cow period.
WO2013036610A3 (en) Compositions comprising mg53 and methods for the treatment and prevention of airway injury
WO2014205199A3 (en) Compositions and methods for potentiating immune response, enhancing immunotherapy, and increasing vaccine potency
MX369122B (en) Herbal supplements and methods of use thereof.
WO2015054678A3 (en) Human papilloma virus therapeutic vaccine
SG10201807682PA (en) Methods of Treating or Preventing Respiratory Conditions
IN2014MN01594A (en)
SG10201908089VA (en) Novel dosing regimens of celgosivir for the treatment of dengue
WO2014074817A3 (en) Attenuated mannheimia haemolytica vaccines and methods of making and use